Erasca Inc. stock falls after unfavorable Revolution pancreatic cancer study data
Updated
Updated · StocksToTrade · Apr 27
Erasca Inc. stock falls after unfavorable Revolution pancreatic cancer study data
7 articles · Updated · StocksToTrade · Apr 27
Shares dropped 8.42% to $15.54, plunging as much as 10.6% intraday to $15.20 on April 27, 2026.
The selloff reflects market disappointment with the Revolution trial results, despite Erasca holding $276.1M in cash and minimal debt, highlighting ongoing volatility and risk in its biotech pipeline.
Erasca’s valuation remains driven by future drug prospects, with heavy R&D spending and negative earnings. The latest data has shaken confidence, making future clinical updates crucial for investor sentiment.
Erasca's stock plunged 35% despite having $276 million in cash. Is this a bargain or a trap?
Does Erasca's dramatic fall prove the high-stakes biotech investment model is fundamentally broken?
Did a competitor's stunning success set an impossible standard for Erasca's new cancer drug data?
With one drug trial failing and another showing promise, what is the real hope for cancer patients?
Executives sold shares weeks before the crash. Was this simply bad timing or a telling red flag?